Drug Trial Radar · NCT05963074
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
333
Actual
Start
May 30, 2024
Primary completion
Dec 15, 2027
Study completion Mar 19, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Pharmacyclics LLC.
- First posted
- Jul 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).
Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Small Lymphocytic Lymphoma
Interventions
IbrutinibDrug
Ibrutinib capsules will be administered orally.
VenetoclaxDrug
Venetoclax tablets will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Overall Response Rate (ORR)Time frame: Up to 5 years
Locations
74 sites in 8 countries. Site status is shown where the registry gives one.
The Oncology Institute Clinical Research
Cerritos, California
Cancer and Blood Specialty Clinic
Los Alamitos, California
SLO Oncology and Hematology Health Center
San Luis Obispo, California
Providence Medical Foundation
Santa Rosa, California
PIH Health Hospital
Whittier, California
Grand Valley Oncology
Grand Junction, Colorado
Mount Sinai Medical Center Campus
Miami Beach, Florida
The Oncology Institute
North Miami Beach, Florida
Mid Florida Hematology Oncology
Orange, Florida
Boise VA Medical Center
Boise, Idaho
Hope and Healing Cancer Services
Hinsdale, Illinois
Springfield Clinic
Springfield, Illinois
Iowa City VA Health Care System
Iowa City, Iowa
Minnesota Oncology Hematology P A
Minneapolis, Minnesota
Research Medical Center
Kansas City, Missouri
Hunterdon Hematology Oncology
Flemington, New Jersey
Summit Medical Group
Florham Park, New Jersey
Hematology Oncology Associates of Rockland
Nyack, New York
Southeastern Medical Oncology Center
Goldsboro, North Carolina
Oncology Hematology Care
Cincinnati, Ohio
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon
OHSU Knight Cancer Institute
Portland, Oregon
Renovatio Clinical
El Paso, Texas
Texas Oncology-Fort Worth Cancer Center
Fort Worth, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Renovatio Clinical 1
The Woodlands, Texas
Texas Oncology-Gulf Coast
The Woodlands, Texas
Community Cancer Trials of Utah
Ogden, Utah
Virginia Cancer Specialists
Manassas, Virginia
Virginia Oncology Associates
Virginia Beach, Virginia
VA Puget Sound Healthcare System
Seattle, Washington
Northwest Cancer Specialists PC
Vancouver, Washington
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Niagara Health System
St. Catharines, Ontario, Canada
Fakultni nemocnice Brno
Brno-Bohunice, Czechia
Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia
Fakultni Nemocnice Ostrava
Ostrava - Poruba, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia
Ustav Hematologie A Krevni Transfuze
Prague, Czechia
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.